Don A Baldwin

Dr. Don A Baldwin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JFJonathan Foox
Jonathan Foox
STScott W. Tighe
Scott W. Tighe
CNCharles M. Nicolet
Charles M. Nicolet
JZJustin M. Zook
Justin M. Zook
MBMarta Byrska-Bishop
Marta Byrska-Bishop
Christopher MasonChristopher Mason
Christopher Mason

5 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CUCristina Uribe-Alvarez
Cristina Uribe-Alvarez
QLQuynh Lam
Quynh Lam
DBDon A Baldwin
Don A Baldwin
JCJonathan Chernoff
Jonathan Chernoff
Diagnosis of any infectious disease is vital for opportune treatment and to prevent dissemination. RT-qPCR tests for detection of SARS-CoV-2, the causative agent for COVID-19, are ideal in a hospital environment. However, mass testing requires cheaper and simpler tests, especially in settings that lack sophisticated machinery. The most common current diagnostic method is based on nasopharyngeal sample collection, RNA extraction, and RT-qPCR for amplification and detection of viral nucleic acids. Here, we show that samples obtained from nasopharyngeal swabs in VTM and in saliva can be used with or without RNA purification in an isothermal loop-mediated amplification (LAMP)-based assay, with 60–93% sensitivity for SARS-CoV-2 detection as compared to standard RT-qPCR tests. A series of simple modifications to standard RT-LAMP published methods to stabilize pH fluctuations due to salivary acidity resulted in a significant improvement in reliability, opening new avenues for efficient, low-cost testing of COVID-19 infection.

Verified
Journal Article
Open access
PDF file
JWJennifer S. Winn
Jennifer S. Winn
ZHZachary Hasse
Zachary Hasse
MSMichael Slifker
Michael Slifker
JPJianming Pei
Jianming Pei
SASebastian M. Arisi-Fernandez
Sebastian M. Arisi-Fernandez
Sandra Viviana FernandezSandra Viviana Fernandez
Sandra Viviana Fernandez
We studied genomic alterations in 19 inflammatory breast cancer (IBC) patients with advanced disease using samples of tissue and paired blood serum or plasma (cell-free DNA, cfDNA) by targeted next generation sequencing (NGS). At diagnosis, the disease was triple negative (TN) in eleven patients (57.8%), ER+ Her2- IBC in six patients (31.6%), ER+ Her2+ IBC in one patient (5.3%), and ER- Her2+ IBC in one other patient (5.3%). Pathogenic or likely pathogenic variants were frequently detected in TP53 (47.3%), PMS2 (26.3%), MRE11 (26.3%), RB1 (10.5%), BRCA1 (10.5%), PTEN (10.5%) and AR (10.5%); other affected genes included PMS1, KMT2C, BRCA2, PALB2, MUTYH, MEN1, MSH2, CHEK2, NCOR1, PIK3CA, ESR1 and MAP2K4. In 15 of the 19 patients in which tissue and paired blood were collected at the same time point, 80% of the variants detected in tissue were also detected in the paired cfDNA. Higher concordance between tissue and cfDNA was found for variants with higher allele fraction in tissue (AFtissue ≥ 5%). Furthermore, 86% of the variants detected in cfDNA were also detected in paired tissue. Our study suggests that the genetic profile measured in blood cfDNA is complementary to that of tumor tissue in IBC patients.

Verified
Journal Article
Open access
PDF file
Sandra Viviana FernandezSandra Viviana Fernandez
Sandra Viviana Fernandez
YTYinfei Tan
Yinfei Tan
SRShilpa Rao
Shilpa Rao
PFPatricia Fittipaldi
Patricia Fittipaldi
FSFathima Sheriff
Fathima Sheriff
DBDon A Baldwin
Don A Baldwin
A modified version of the PGDx elioTM Plasma Resolve assay was validated as a laboratory-developed test (LDT) for clinical use in the Molecular Diagnostics Laboratory at Fox Chase Cancer Center. The test detects single nucleotide variants (SNVs) and small insertions and deletions (indels) in 33 target genes using fragmented genomic DNA extracted from plasma. The analytical performance of this assay was assessed with reference standard DNA and 29 samples from cancer patients and detected 66 SNVs and 23 indels. Using 50 ng of input DNA, the sensitivity was 95.5% to detect SNVs at 0.5% allele frequency, and the specificity was 92.3%. The sensitivity to detect indels at 1% allele frequency was 70.4%. A cutoff of 0.25% variant allele frequency (VAF) was set up for diagnostic reporting. An inter-laboratory study of concordance with an orthologous test resulted in a positive percent agreement (PPA) of 91.7%.

11 October 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JFJonathan Foox
Jonathan Foox
STScott W. Tighe
Scott W. Tighe
CNCharles M. Nicolet
Charles M. Nicolet
JZJustin M. Zook
Justin M. Zook
MBMarta Byrska-Bishop
Marta Byrska-Bishop
Christopher MasonChristopher Mason
Christopher Mason

5 December 2022 in Journal of Biomolecular Techniques : JBT
Verified
Journal Article
Open access
PDF file
DBDon A Baldwin
Don A Baldwin
CGCheyenne R. Gigli
Cheyenne R. Gigli
TKTim Kwok
Tim Kwok
SCSharon Connelly
Sharon Connelly
JHJames L. Helstrom
James L. Helstrom
EHEric M. Horwitz
Eric M. Horwitz
Background: Supply chain disruptions during the COVID-19 pandemic have affected the availability of components for specimen collection kits to detect SARS-CoV-2. Plastic injection molding offers a rapid and cheap method for mass production of swabs for upper respiratory tract sampling. Local production of virus transport medium increases flexibility to assemble sample collection kits if the medium provides appropriate stability for SARS-CoV-2 detection. Methods: A locally produced virus transport medium and a novel injection molded plastic swab were validated for SARS-CoV-2 detection by reverse-transcription quantitative polymerase chain reaction. Both components were compared to standard counterparts using viral reference material and representative patient samples. Results: Clinical testing showed no significant differences between molded and flocked swabs. Commercial and in-house virus transport media provided stable test results for over 40 days of specimen storage and showed no differences in test results using patient samples. Conclusions: This collection kit provides new supply chain options for SARS-CoV-2 testing.